



# Paediatric Infection Prevention and Control

Dr Alison Kent

Paediatric Infectious Diseases and Immunology  
Consultant

Evelina London Children's Hospital

© Mike Baldwin / Cornered

BALDWIN




“The patient in the next bed is highly infectious. Thank God for these curtains.”

# What is a healthcare associated infection (HCAI)?

Infection which has become apparent  $\geq 48$  hours into hospital admission, or within 30 days following discharge from inpatient care

i.e. was not present or incubating at the time of admission




# Why are we talking about it?

Common and severe

>1000 deaths neonatal sepsis / year directly attributable to HCAI

75% of AMR burden in Europe due to healthcare-associated infections





ARTICLES · Volume 17, Issue 4, P381-389, April 2017


[Download Full Issue](#)

Health-care-associated infections in neonates, children, and adolescents: an analysis of paediatric data from the European Centre for Disease Prevention and Control point-prevalence survey



[Dr Walter Zingg, MD](#) <sup>a,b</sup>  · [Susan Hopkins, MD](#) <sup>c,d</sup> · [Angèle Gayet-Ageron, MD](#) <sup>b</sup> ·

[Prof Alison Holmes, MD](#) <sup>a,d</sup> · [Mike Sharland, MD](#) <sup>e</sup> · [Carl Suetens, MD](#) <sup>f</sup> · et al. [Show more](#)

- 2011-2012, ECDC
- 1149 hospitals, 29 countries
- 17 273 children
  
- 770 HCAI = 4.2%
- PICU 15.5%
- NICU 10.7%




- Bloodstream infections
- Lower respiratory tract infections
- Urinary tract infections
- Surgical site infections
- Gastrointestinal infections
- Eye, ear, nose, and throat infections
- Other infections





Healthcare-associated infections
Healthcare-associated <i>Clostridium difficile</i> infection (HA CDI)
Healthcare-associated pneumonia (HAP)
Healthcare-associated neonatal sepsis
Healthcare-associated primary bloodstream infection (HA primary BSI)
Healthcare-associated surgical site infection (HA SSI)
Healthcare-associated urinary tract infection (HA UTI)
doi:10.1371/journal.pone.0170662.t001





Campylobacteriosis
Chlamydia
Congenital Toxoplasmosis
Cryptosporidiosis
Diphtheria
Giardiasis
Gonococcal infections
Hepatitis A
Hepatitis B
Hepatitis C
HIV/AIDS
Infection with STEC/VTEC
Influenza
Invasive <i>Haemophilus influenzae</i> disease
Invasive meningococcal disease
Invasive pneumococcal infections
Legionnaires' disease
Listeriosis
Measles
Mumps
Pertussis
Poliomyelitis
Q fever
Rabies
Rubella
Salmonellosis
Shigellosis
Syphilis
Tetanus
Tick-borne encephalitis
Tuberculosis
Variant Creutzfeldt-Jakob disease



2x



# The Iceberg Effect



1 day –  
2  
weeks


Colonisation



Infection

CLABSI

HAP/VAP





# Why Contact Precautions\* for MDRO are Important

## STUDY:

- Observational study of clinical care of MDRO+ patients
- Cultures of gloves, gowns, and hands after care

## MDRO contamination present after:

- 77 of 199 (38.7%) on gowns OR gloves
- 9 of 199 (4.5%) on hands **after glove removal\***


*\*after glove removal but before HH*

# Paediatric-specific challenges

- Shed more, for longer...

Children aged <5 years shed more virus than other age groups.

Associations between age group and viral shedding summary metrics: (A) day of shedding clearance relative to ILI onset; (B) day of shedding onset relative to ILI onset; (C) day of peak shedding relative to ILI onset; (D) duration of shedding in days; (E) Peak value of shedding attained (transformed as  $40 - Ct$ ); and (F) total virus shed, as measured by the area under the fitted shedding curve. ILI represents influenza-like-illness and AUC represents the area under the curve. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ .




## Paediatric-specific challenges

- Shed more, for longer...
- No personal space...(poor cough etiquette, close contact play, mouthing)
- Family involvement: more people = more vectors
- Not a fan of PPE
- Vaccination gaps / catch up schedules



# Core Infection Prevention Measures

- Hand hygiene
- Bare below the elbows
- Standard and transmission-based precautions
- Environmental & equipment hygiene





Overview of the use of standard and transmission-based precautions										
Type of precautions	Examples of infectious agents	Patient placement	Gloves	Gowns	Masks	Protective eyewear	Shared equipment	Environmental cleaning	Visitors*	
Standard precautions	Hepatitis B, Hepatitis C, Cytomegalovirus (CMV)	No restrictions on patient placement.	<b>PPE use:</b> <ul style="list-style-type: none"> <li>Gloves and gowns to be worn when there is potential exposure to blood or body substances</li> <li>Mask and protective eyewear to be worn when there is potential for blood or body substances exposure to mucosa (for e.g., attending to a patient who is coughing and sneezing).</li> </ul>				Single-use, single - patient use or reprocess	Clean with neutral detergent. If surfaces are contaminated with blood or body fluids, cleaning should be followed with disinfection.	Hand hygiene, respiratory hygiene, cough etiquette.	
Contact	Multidrug-resistant organisms, <i>C.difficile</i> , norovirus	Single room, or cohort with same strain of infectious agent.	Yes	Yes	As per standard precautions	As per standard precautions		Neutral detergent and disinfectant are required.	As per standard precautions	
Droplet <sup>^</sup>	Norovirus, pertussis <sup>#</sup> , meningococcus	Single room with door open, or cohort with same strain of infectious agent.	As per standard precautions	As per standard precautions	Yes- use surgical mask			As per standard precautions	Neutral detergent. Use disinfectant if infectious agent is a multidrug-resistant organism or in the event of an outbreak.	Restrict visitor numbers and use same precautions as staff.
Airborne	Pulmonary TB, rubella <sup>#</sup> , measles <sup>#</sup> and chicken pox <sup>#</sup>	Single room with door closed. Use negative pressure room if available.			Yes- use particulate respirator (P2 or N95 mask)					



# But there's not enough side rooms..

Organism / infection (suspected or confirmed) - the following require <a href="#">isolation</a> and discussion with the <a href="#">Infection Control Team</a> . They are listed in order of priority (high to low). Click <a href="#">here</a> to access further information.	Priority score for isolation (1 to 9, where 9 is highest)
Epiglottitis or Supraglottitis (Pending laboratory results, as these can be caused by Haemophilus influenzae type b or Streptococcus pyogenes (Group A Strep))	9
Haemophilus influenzae type b causing any infection - <b>Notifiable disease</b>	9
Diarrhoea and/or vomiting of potentially infectious cause (pending laboratory results)	8
Clostridium difficile	8
E. coli O157 – <b>Notifiable disease</b>	8
Shigella	8
Streptococcus pyogenes (Group A Strep) causing any infection. Invasive Group A Strep is a <b>Notifiable disease</b>	8
Influenza	7
Neisseria meningitidis, causing meningitis or septicaemia (until 24hrs of appropriate antibiotics) - <b>Notifiable disease</b>	7
Mumps - <b>Notifiable disease</b>	7
Whooping Cough (Bordetella pertussis) - <b>Notifiable disease</b>	6
Respiratory syncytial virus (RSV)	6
Mycobacterium tuberculosis (TB) extra-pulmonary - <b>Notifiable disease</b>	6
Shingles	5
Vancomycin Resistant Enterococcus (VRE)	5
Salmonella	5
Acute viral encephalitis, of all causes including herpes simplex virus (HSV)	4
Extended Spectrum Beta Lactamase (ESBL) producing organisms, symptomatic of infection	4
Common cold (not including RSV or influenza)	2
Lice	2
Rotavirus	2
Scabies	2
Campylobacter	1
Cryptosporidium	1

MRSA - different isolation priority scores apply depending on patient factors and patient location. 'Skin shedders' include patients with eczema and psoriasis	Priority score for isolation (1 to 9, where 9 is highest)
<b>For patients currently in UHC or UHA</b>	
MRSA in sputum, multiple sites, or skin shedders	8
MRSA in nose only	5
MRSA Clinical Risk Assessment positive (yes to any question)	5
<b>For patients currently in a community hospital or GP unit</b>	
MRSA in sputum, multiple sites, or skin shedders	6
MRSA in nose only (applies to GP units only)	3

# Contact and droplet precautions - rediroom



# Paediatric respiratory infection challenges

- Seasonality and outbreak management
- Cohorting vs single room isolation
- Aerosol generating procedures
- Carriage vs infectivity





## Managing children requiring admission to hospital with viral respiratory tract infections: summary flow chart (November 2025)

During periods of high respiratory virus prevalence, cubicles should be prioritised for children at the highest risk of severe disease\*

All staff involved in the care of symptomatic children must wear personal protective equipment (PPE) in accordance with appropriate transmission-based precautions.

Child requiring admission to hospital with presumed viral respiratory tract infection

Perform respiratory viral testing (RSV, influenza A/B, SARS-CoV-2).  
Use rapid molecular testing where locally agreed. If limited testing capacity, prioritise rapid testing for children in whom AGPs are likely to be performed. NOTE: transfer from ED should not be delayed while awaiting viral results

Can initially be admitted to an undifferentiated respiratory bay whilst awaiting respiratory virus results unless AGP being performed (see Appendix 2).

### Management of RSV or influenza positive children

Transfer to virus specific cohort bay or cubicle irrespective of whether an AGP is being performed.

De-escalate when appropriate\*\*

### Management of RSV or influenza negative children

(these children may be positive for other respiratory viruses including SARS-CoV-2)  
Can manage in a non-RSV, non-influenza A/B respiratory cohort area.

De-escalate when appropriate\*\*

# Device related and procedural infection prevention

- CLABSI bundles and audits
- VAP prevention
- Catheter associated UTI
- ANTT
- Consideration for neonates – skin integrity, umbilical lines



Evelina  
London

## Neonates

### Why?

Immature immune system

Poor skin integrity

Long duration of stay

Many high-dependency patients in open bays

Longer duration of CVC access (i.e. PN)







## How / when do CLABSIs occur?

CLABSI

- **During catheter insertion**
- At time of dressing change
- When catheter is being accessed

Opportunities to improve practice



**Table 1.** Summary of Recommendations to Prevent CLABSI

Essential Practices
<p><i>Before insertion</i></p> <ol style="list-style-type: none"> <li>1. Provide easy access to an evidence-based list of indications for CVC use to minimize unnecessary CVC placement (Quality of Evidence: LOW)</li> <li>2. Require education and competency assessment of HCP involved in insertion, care, and maintenance of CVCs about CLABSI prevention (Quality of Evidence: MODERATE)<sup>74-78</sup></li> <li>3. Bathe ICU patients aged &gt;2 months with a chlorhexidine preparation on a daily basis (Quality of Evidence: HIGH)<sup>86-90</sup></li> </ol> <p><i>At insertion</i></p> <ol style="list-style-type: none"> <li>1. In ICU and non-ICU settings, a facility should have a process in place, such as a checklist, to ensure adherence to infection prevention practices at the time of CVC insertion (Quality of Evidence: MODERATE)<sup>101</sup></li> <li>2. Perform hand hygiene prior to catheter insertion or manipulation (Quality of Evidence: MODERATE)<sup>102-107</sup></li> <li>3. The subclavian site is preferred to reduce infectious complications when the catheter is placed in the ICU setting (Quality of Evidence: HIGH)<sup>33,37,108-110</sup></li> <li>4. Use an all-inclusive catheter cart or kit (Quality of Evidence: MODERATE)<sup>118</sup></li> <li>5. Use ultrasound guidance for catheter insertion (Quality of Evidence: HIGH)<sup>119,120</sup></li> <li>6. Use maximum sterile barrier precautions during CVC insertion (Quality of Evidence: MODERATE)<sup>123-128</sup></li> <li>7. Use an alcoholic chlorhexidine antiseptic for skin preparation (Quality of Evidence: HIGH)<sup>42,129-134</sup></li> </ol> <p><i>After insertion</i></p> <ol style="list-style-type: none"> <li>1. Ensure appropriate nurse-to-patient ratio and limit use of float nurses in ICUs (Quality of Evidence: HIGH)<sup>34,35</sup></li> <li>2. Use chlorhexidine-containing dressings for CVCs in patients over 2 months of age (Quality of Evidence: HIGH)<sup>45,135-142</sup></li> <li>3. For non-tunneled CVCs in adults and children, change transparent dressings and perform site care with a chlorhexidine-based antiseptic at least every 7 days or immediately if the dressing is soiled, loose, or damp. Change gauze dressings every 2 days or earlier if the dressing is soiled, loose, or damp (Quality of Evidence: MODERATE)<sup>145-148</sup></li> <li>4. Disinfect catheter hubs, needleless connectors, and injection ports before accessing the catheter (Quality of Evidence: MODERATE)<sup>150-154</sup></li> <li>5. Remove nonessential catheters (Quality of Evidence: MODERATE)</li> <li>6. Routine replacement of administration sets not used for blood, blood products, or lipid formulations can be performed at intervals up to 7 days (Quality of Evidence: HIGH)<sup>164</sup></li> <li>7. Perform surveillance for CLABSI in ICU and non-ICU settings (Quality of Evidence: HIGH)<sup>13,165,166</sup></li> </ol>
Additional Approaches
<ol style="list-style-type: none"> <li>1. Use antiseptic- or antimicrobial-impregnated CVCs (Quality of Evidence: HIGH in adult patients<sup>38,39,169-171</sup> and Quality of Evidence: MODERATE in pediatric patients)<sup>172,173</sup></li> <li>2. Use antimicrobial lock therapy for long-term CVCs (Quality of Evidence: HIGH)<sup>177-184</sup></li> <li>3. Use recombinant tissue plasminogen activating factor (rt-PA) once weekly after hemodialysis in patients undergoing hemodialysis through a CVC (Quality of Evidence: HIGH)<sup>192</sup></li> <li>4. Utilize infusion or vascular access teams for reducing CLABSI rates (Quality of Evidence: LOW)<sup>193,194</sup></li> <li>5. Use antimicrobial ointments for hemodialysis catheter insertion sites (Quality of Evidence: HIGH)<sup>197-201</sup></li> <li>6. Use an antiseptic-containing hub/connector cap/port protector to cover connectors (Quality of Evidence: MODERATE)<sup>202-208</sup></li> </ol>
Approaches that Should Not Be Considered a Routine Part of CLABSI Prevention
<ol style="list-style-type: none"> <li>1. Do not use antimicrobial prophylaxis for short-term or tunneled catheter insertion or while catheters are <i>in situ</i> (Quality of Evidence: HIGH)<sup>209-213</sup></li> <li>2. Do not routinely replace CVCs or arterial catheters (Quality of Evidence: HIGH)<sup>214</sup></li> </ol>
Unresolved Issues
<ol style="list-style-type: none"> <li>1. Routine use of needleless connectors as a CLABSI prevention strategy before an assessment of risks, benefits, and education regarding proper use<sup>215-219</sup></li> <li>2. Surveillance of other types of catheters (eg, peripheral arterial or peripheral venous catheters)<sup>11,21,22</sup></li> <li>3. Standard, nonantimicrobial transparent dressings and CLABSI risk.</li> <li>4. The impact of using chlorhexidine-based products on bacterial resistance to chlorhexidine</li> <li>5. Sutureless securement</li> <li>6. Impact of silver zeolite-impregnated umbilical catheters in preterm infants (applicable in countries where it is approved for use in children)<sup>227</sup></li> <li>7. Necessity of mechanical disinfection of a catheter hub, needleless connector, and injection port before accessing the catheter when antiseptic-containing caps are being used</li> </ol>

Note. CLABSI, central line-associated bloodstream infection; CVC, central venous catheter; HCP, healthcare personnel; ICU, intensive care unit.

Infection Control & Hospital Epidemiology (2022), 43, 553-569  
doi:10.1017/ice.2022.87



**SHEA/IDSA/APIC Practice Recommendation**

**Strategies to prevent central line-associated bloodstream infections in acute-care hospitals: 2022 Update**

Niccolò Buetti MD, MSc, PhD<sup>1,2,a</sup>, Jonas Marschall MD, MSc<sup>3,4,a</sup>, Marci Drees MD, MS<sup>5,6</sup>,  
Mohamad G. Fakhri MD, MPH<sup>7</sup>, Lynn Hadaway MEd, RN, NPD-BC, CRNI<sup>8</sup>, Lisa L. Maragakis MD, MPH<sup>9</sup>,  
Elizabeth Monsees PhD, MBA, RN, CIC<sup>10,11</sup>, Shannon Novosad MD MPH<sup>12</sup>, Naomi P. O'Grady MD<sup>13</sup>,  
Mark E. Rupp MD<sup>14</sup>, Joshua Wolf MBBS, PhD, FRACP<sup>15,16</sup>, Deborah Yokoe MD, MPH<sup>17</sup> and  
Leonard A. Mermel DO, ScM<sup>18,19</sup>



## Key points

HCAI are a big and increasing problem

IPC precautions like the CQC are watching!

Think about which precautions and apply consistently with signage

Focus on lines

